CTOs on the Move

Axm Pharma

www.axmpharma.com

 
AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.axmpharma.com
  • 7251 W Lake Mead Blvd Ste 300
    Las Vegas, NV USA 89128
  • Phone: 702.562.4155

Executives

Name Title Contact Details

Similar Companies

Pediatrics Plus

Pediatrics Plus is a specialized pediatric healthcare provider committed to helping your child succeed in all stages of life through therapy and education.

Galderma Canada

Galderma Canada Inc. is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sunrise Treatment Center

We are a substance abuse treatment program focusing primarily on opioid use disorders. We have locations in Cincinnati, Forest Park, Middletown, and Dayton. Services include individual and group counseling, urinalysis, case management, and cri...

Mylan Pharmaceuticals Inc

Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of

Monte Rosa Therapeutics

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.